Evidence map›Paper›PMID 38224427›Full record

ArticleBreast cancer research and treatment2024

Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors.

Alexander S Bang, Christopher J Fay, Nicole R LeBoeuf, Farshid Etaee, Jonathan S Leventhal, Vincent Sibaud, Joshua Arbesman, Jennifer Y Wang, Bernice Y Kwong

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Survey of Drugs Induced Skin Pigmentation (Hyper and Hypo Pigmentation).Clinical, cosmetic and investigational dermatology · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Alexander S BangDepartment of Dermatology, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-1700-2411
Christopher J FayDermatology of Dermatology, Harvard Medical School, Center for Cutaneous Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA, USA.
Nicole R LeBoeufDermatology of Dermatology, Harvard Medical School, Center for Cutaneous Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA, USA.
Farshid EtaeeDepartment of Dermatology, Yale School of Medicine, New Haven, CT, USA.
Jonathan S LeventhalDepartment of Dermatology, Yale School of Medicine, New Haven, CT, USA.
Vincent SibaudOncodermatology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
Joshua ArbesmanDepartment of Dermatology, Cleveland Clinic, Cleveland, OH, USA.
Jennifer Y WangDepartment of Dermatology, Stanford University, Palo Alto, CA, USA.
Bernice Y KwongDepartment of Dermatology, Stanford University, Palo Alto, CA, USA. bernicek@stanford.edu.
Brigham and Women's Hospital · USPalo Alto University · USYale University · USCleveland Clinic · USInstitut universitaire du cancer de Toulouse Oncopole · FRMemorial Sloan Kettering Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCutaneous adverse effects from cyclin-dependent 4 and 6 kinase inhibitors (CDK4/6i) used in metastatic breast cancer are prevalent and well described. Vitiligo-like lesions have been reported and are rare. They can negatively impact patients' quality of life and may be associated with survival benefits. We describe the clinical characteristics of vitiligo-like lesions in an international cohort of patients treated with CDK4/6i to help improve recognition and management.

methodsRetrospective review of patients diagnosed with vitiligo-like lesions from CDK4/6i from five academic institutions in the USA and Europe was performed. Ten patients were included in the study.

resultsMedian age of our patients was 55 (range 37-86). Median progression-free survival was 24 months in 5 patients. The median time to rash was 10 months. Sun-exposed areas such as the arms and face were the most affected areas. Multiple skin-directed therapies such as topicals, laser, and phototherapy were trialed with minor success. Mild repigmentation was seen in one patient treated with ruxolitinib cream. CDK4/6 treatment was discontinued due to the vitiligo-like lesions in one patient.

conclusionClinical characteristics are similar to previously reported findings in case reports and series. We add topical ruxolitinib as a potential treatment option for these patients and include data regarding progression-free survival that should continue to be collected. No definitive conclusions can be made regarding survival benefits from our cohort. Clinicians should refer these patients to dermatologists to aid with management.

Indexed as

Breast NeoplasmsNitrilesPyrazolesPyrimidinesVitiligoAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsCyclin-Dependent Kinase 4FemaleHumansProtein Kinase InhibitorsPyridinesQuality of LifeRetrospective StudiesAminopyridinesCyclin-Dependent Kinase 4NitrilesProtein Kinase InhibitorsPyrazolesPyridinesPyrimidinesruxolitinibAbemaciclibCDK4/6 inhibitorsDermatologic adverse eventOncodermatologyPalbociclibRibociclibVitiligoVitiligo like

Identifiers

PMID38224427
OpenAlexW4390878811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.